Meeting
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
Authors
Jonathan Mizrahi
University of Texas MD Anderson Cancer Center, Houston, TX
Jonathan Mizrahi , Jane Rogers , Kenneth R. Hess , Robert A. Wolff , Gauri Rajani Varadhachary , Rachna T. Shroff , Linus Ho , David R. Fogelman , Kanwal Pratap Singh Raghav , Michael J. Overman , Shubham Pant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 362)
DOI
10.1200/JCO.2019.37.4_suppl.362
Abstract #
362
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2016 Gastrointestinal Cancers Symposium
Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study.
First Author: Robert de Wilton Marsh
Poster
2015 Gastrointestinal Cancers Symposium
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).
First Author: Daniel A. Goldstein